Physician profile
Bhavya Akhauri
NPI 1639332745
$2,226.97
in general payments reported to CMS, 2019-2025
22 companies · $702 in 2025
The $702 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.02 · 2020: $58.45 · 2021: $170 · 2022: $341 · 2023: $457 · 2024: $416 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,574.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $698.84 | 2019-2025 | Rinvoq, Viberzi, Linzess |
| Janssen Biotech, INC. | $426.21 | 2019-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $151.46 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $121.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $116.80 | 2019-2024 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $112.89 | 2023-2024 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.36 | 2021-2024 | Xifaxan |
| Ardelyx, INC. | $83.95 | 2023-2025 | Ibsrela |
| Celgene Corporation | $73.91 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $67.57 | 2021-2025 | |
| Pfizer INC. | $42.51 | 2021-2024 | |
| Intercept Pharmaceuticals, INC. | $39.62 | 2024-2025 | |
| Boston Scientific Corporation | $35.03 | 2019-2023 | |
| Aimmune Therapeutics, INC. | $29.52 | 2024 | |
| Medtronic, INC. | $24.92 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $24.66 | 2023 | Linzess |
| Fresenius Kabi USA, LLC | $20.94 | 2025 | |
| Merck Sharp & Dohme LLC | $16.50 | 2023 | Dificid |
| Celltrion USA INC. | $15.04 | 2025 | Vegzelma |
| Genzyme Corporation | $14.64 | 2024 | |
| Braintree Laboratories, INC. | $13.82 | 2022 | |
| Allergan, INC. | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhavya Akhauri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.